CeNeS extends US collaboration
Cambridge’s CeNeS Phar-maceuticals has extended its research collaboration with US-based Tripos, Inc, a provider of drug discovery chemistry and informatics products and services, to developinhibitors for the treatment of Parkinson’s disease.
Terms of the agreement whose origins stretch back to 2003 were not disclosed.
Using Tripos’ knowledge-driven chemistry process to investigate the inhibition of enzyme catechol-O-methyltransferase (COMT) with analogues of CeNeS’ own proposed leads, the two succeeded in
identifying several series of novel active compounds, thereby achieving a chemical breakaway from currently marketed COMT inhibitors.
Tripos and CeNeS are now jointly developing these lead series with a view to further optimising in vitro and in vivo activity as well as their ADMET – absorption, distribution, excretion, metabolism and
toxicity – profile, thus addressing the known limitations associated with existing marketed therapies.
Dr Gary Tilbrook, chemistry director for CeNeS, said: “Our COMT discovery program has continued to perform to plan and we are excited about its potential to deliver improved therapies for the treatment of Parkinson’s disease.”